Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer
Maria Vittoria Dieci(Istituto Oncologico Veneto), Valentina Guarneri(Istituto Oncologico Veneto), Anita Rimanti(Azienda Ospedaliera Carlo Poma), Federica Miglietta(University of Padua), Roberto D’Amico(University of Modena and Reggio Emilia), Melinda E. Sanders(Vanderbilt University), Samanta Sarti(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), PierFranco Conte(University of Padua), Sara Balduzzi(Dutch Cancer Society), Giancarlo Bisagni, Antonino Musolino(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Enrico Orvieto(AULSS 2 Marca Trevigiana), Antonio Frassoldati(University of Ferrara), Luigi Cavanna(University of Pavia), Francesco Giotta(Istituto Tumori Bari), Alba A. Brandes(Istituto delle Scienze Neurologiche di Bologna), Federico Piacentini(Azienda Unita' Sanitaria Locale Di Modena), Antonella Ferro(Ospedale Santa Chiara), Antonino Maiorana(University of Modena and Reggio Emilia), Elena Bertone, Ornella Garrone(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo)
Cited by 96
Related Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
|JAMA Oncology|2019|983
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830